Back

Latest Forum Topics / Biosensors

Post Reply

Is Biosensors a good buy? Post Reply Rate topic
techsys Master	22-Sep-2007 11:34        techsys About Contact  Quote this Post! Style: Combined   Mood:
x 2   x 0  Alert Admin	Biosensor is proposing for aqcusition 50% stake of JW Medical System. http://www.listedcompany.com/ir/biosensors/newsroom/AIP_Announcement210907.pdf Let's wait and see .. :)
Useful To Me  Not Useful To Me
renewal Member	20-Sep-2007 21:39        renewal About Contact  Quote this Post!
x 0   x 0  Alert Admin	Thanks for the info. Think the stock is the still in the process of consolidation. Will be a while.
Useful To Me  Not Useful To Me
investor Senior	20-Sep-2007 20:47        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	Xtent, who is Biosensors' licensee has given an 'investors conference' on the 17th Sep 2007. Details are available on the Xtent's website. They have given a guidance that they are 'on track' to get the US IDE approval in the 2nd half of 2007 (ie the remaining mths of 2007), and will probably be able to start enrolling patients for the US pivotal trial, also towards end of this yr. They will also be submitting approval for CE Mark in 2nd half of 2007, and expects to get the CE Mark approval in 2nd half of 2008. (Projected). For info.
Useful To Me  Not Useful To Me
investor Senior	20-Sep-2007 11:41        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	Latest update from the coming TCT2007 conference commencing on 20th Oct 2007. Biosensors will present - Technical Review and Clinical Trial Updates for Stealth, BEACON, and LEADERS trial - 21st Oct 2007 (2.44pm) Terumo will present - NOBURI -Phase I - Update and Preview of Phase II trial. - 21st Oct 2007 (2.56 pm) Devaxx will present - AXXES self-expanding stent for Bifurcations - 21st Oct 2007 (3.06pm) Xtent will present - CUSTOM trials - 21st Oct 2007 (3.16pm) The above represents the 'family' of Biolimus drug using a bio-degradable polymer DES system. For info - not an inducement to trade.
Useful To Me  Not Useful To Me
investor Senior	14-Sep-2007 11:24        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	One more thing to add - If the stock closes below 0.66 (which is its 20 day mva), then the technical picture will not look too good. We will then have a situation where the stock is still 'consolidating' and trying to find a bottom.
Useful To Me  Not Useful To Me
investor Senior	14-Sep-2007 10:57        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	The technical picture for Biosensors looks better. The stock has cleared above its 20 day mva, yesterday, and if it stays above that, hopefully we can see the next target price at 0.75 (50 days mva. Using candlestick terminology, yesterday's closing patttern, which resembles a 'shooting star' does not look bullish, but it can be negated if the stock closes above yesterday's closing price.
Useful To Me  Not Useful To Me
bengster68 Master	14-Sep-2007 10:13        bengster68 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yeah........ Hopefully not free heart stents for shareholders. Hehehe!
Useful To Me  Not Useful To Me
novena_33 Veteran	13-Sep-2007 22:40        novena_33 About Contact  Quote this Post!
x 0   x 0  Alert Admin	well...lets hope...we all have some christmas present for this yrs..... from Bio
Useful To Me  Not Useful To Me
lomodes Member	13-Sep-2007 21:07        lomodes About Contact  Quote this Post!
x 0   x 0  Alert Admin	I think its worth to buy Biosensors. In 13 Sept'07 Businesstimes, it wrote that Group President Mr Chua Kee-Lock was optimistic with regards to their new business unit. Moreover, they are currently under an attempt to get the regulatory approval to enter the European market which poses good business prospects in the long run.
Useful To Me  Not Useful To Me
bengster68 Master	13-Sep-2007 20:15        bengster68 About Contact  Quote this Post!
x 0   x 0  Alert Admin	That will be the first trading halt. With the current better sentiments on DES, the CE has lesser excuse to further delay approval. Im banging on the mother of all biosensor's halt and i personally feel there is a very high chance of it happening from Nov 2007 to June 2008. The opening price will be $3 and everyone HUAT AH!!! If it doesn't happen, our consolation prize will be listing in NASDAQ.
Useful To Me  Not Useful To Me
jackjames Elite	13-Sep-2007 17:27        jackjames About Contact  Quote this Post!
x 0   x 0  Alert Admin	folks, no worries, either u buy at 0.58, 0.63, 0.69, or even 0.705 today, one fine day, it will be halt, and the next time opening price will be 1.10 , then, everybody wins
Useful To Me  Not Useful To Me
bengster68 Master	13-Sep-2007 16:58        bengster68 About Contact  Quote this Post!
x 0   x 0  Alert Admin	I think they will do something similar like the Indonesian deal in India, Taiwan, Korea, Thailand, etc. The polymer free stent President Chua is talking about is BIOMATRIX-FREEDOM. They had successful animal clinical trials and already moved to human clinical trials on very small scale. BIG is a pioneer in biodegredable polymer and totally polymer free for DES. BIG has the foresight and already years ahead for this technology. What a waste this technology cannot benefit patients earlier due to business rivalry and politics problems that are causing CE delay. Those bastards at Netherlands CE panel must be fully investigated for corruption!!!
Useful To Me  Not Useful To Me
investor Senior	13-Sep-2007 15:39        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	Reuters News reported an interview with Chua kee Lock, President of Biosensors conducted on Thursday. He says that Biosensors intend to expand into India, Korea, Taiwan within one year. He also expects China unit to start contributing to earnings in one to two mths, after acquisition, which should be completed by Oct 07. Their next generation stents, ie the 'polymerless' stent or the biodegradable stent (I presume) should get European approval within 4 yrs.
Useful To Me  Not Useful To Me
bengster68 Master	13-Sep-2007 15:17        bengster68 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Kam Siah abc2xyz. Hope your Abbott huat also. ABBOTT: A PROMISE FOR LIFE.  From OCBC Securities: Summary: Positive clinical studies surrounding Drug Eluting Stents (DES) from the recent European Society of Cardiology Congress would bode well for DES makers like Biosensors International Group (BIG). Long term findings about the effects of DES involving large and diverse patient pools (536 ? 13,786 patients) were presented. All these studies inherently pointed to the fact that the mortality rates for DES as compared to Bare Metal Stents (BMS) in the long term are statically insignificant thus bringing better peace of mind to clinicians administering DES to patients. We think that the good vibes surrounding DES generated from the congress will act to sooth regulatory nerves to grant next gen DES makers like BIG their CE mark as their stents aim to address present day concerns of late stent thrombosis and vascular restenosis. We maintain our forecasts from management?s last guidance though we are mindful that the CE mark delay has slowed sales ramp up. However, we see that JWMS? contribution may buffer its loss of sales. We expect management to give guidance in 2Q08. Maintain BUY at fair value of S$1.21. Cheers for DES makers. The recent European Society of Cardiology Congress from 1 - 5 Sep 07 in Vienna generated news that restored cheer to Drug Eluting Stent (DES) makers. Good clinical study outcomes for DES were presented by major DES producers, most notably from Boston Scientific (BSX) and Cordis (J&J). Long term (c. 4-5 years) controlled study data that involved large and diverse patient pools (536 ? 13,786 patients) were presented. Pivotal studies presented included BSX?s TAXUS II trial, J&J?s E-SIRIUS trial and the 4-year 13,786 patients study by the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). All these studies inherently showed that low restenosis benefit of DES far outweighed the statically insignificant mortality risk of late stent thrombosis. Statistics vs. pain. The studies reiterated that blot clots still do occur when using DES, though at a minute statistical occurrence of about 0.5%. However, when compared to the average 50% reduction of re-narrowing arteries, which typically calls for another stent to be painfully and expensively implanted, the appeal of DES is starting to glow again. These studies now present clinicians with greater clarity in selection and implantation. Soothing regulatory nerves. Biosensors? (BIG) CE mark has now taken about 6 months longer than Conor?s and we think that the good vibes surrounding DES generated from the congress will act to sooth regulatory nerves to grant DES makers like BIG their CE mark. Management has iterated that authorities have not requested additional resource intensive clinical trials. BIG solution to the ?small? problem. Despite the positive study outcomes and better stance towards DES, the inherent problem of late stent thrombosis still occurs, though at a ?small? rate of about 0.5%. BIG?s Biomatrix DES with biodegradable polymer aims to address vascular re-narrowing by eluting its proprietary anti-restenosis drug Biolimus A9 and later converts to a BMS to solve the problem of late stent thrombosis. Attractive price, iterate BUY. Being mindful of the regulatory delay, we still maintain our forecasts from management?s last guidance as we see that JWMS? contribution may buffer its loss of sales from the CE mark delay. Management is expected to give guidance in 2Q08. Maintain BUY at fair value of S$1.21. Controlled studies general information: TAXUS II is a randomized, double-blind, controlled study of 536 patients in 15 countries designed to evaluate the safety and efficacy of a TAXUS paclitaxel-eluting coronary stent, in which two sequential cohorts of patients with standard risk, de novo coronary artery lesions were treated with different dose formulations. Source: Boston Scientific The E-SIRIUS trial is a double blind, multi-center, controlled, randomized trial designed to compare restenosis (re-blockage) rates between the CYPHER(R) Stent and a bare metal stent. It involved 352 patients from 35 European clinical centers. Patients enrolled in the study were considered to be at a moderate to high clinical risk for restenosis due to a previous heart attack or smoking. Source: Cordis (Johnson and Johnson). The Swedish Coronary Angiography and Angioplasty Registry (SCAAR), which included data on 294,000 procedures, was derived from the Swedish Personal Registry, which records all health events occurring in each Swedish individual from 1989 ? 2007. In the registry data, 13,786 patients received a DES and 21,480 a BMS. Analysis of events showed that, within the entire study between 2002 and 2006, 2957 myocardial infarctions (heart attacks) and 1424 deaths occurred - and these provided the outcome measures for the statistical analysis. Source: SCAAR. Current competitive landscape 2 sides of a coin. We managed to catch up with BIG?s CTO, John Shultze, while he was in town. We gleaned keen insights that there seems to be a divergence of stent technologies taken by the 4 main players in the market (J&J, Boston Scientific, Medtronic and Abbott). Medtronic has taken the stance of remaining with durable polymers while the rest have taken steps to develop biodegradable polymer and/or stent technology. J&J will utilise the recently acquired Conor biodegradable polymer in-well platform to incorporate it with the sirolimus drug, Boston Scientific continues to plough ahead with Reva Medical to develop a fully biodegradable stent and Abbott showed positive 9 month clinical results for its ABSORB trial in May 2007 for its biodegradable DES program. We feel that BIG?s foresight 3-4 years ago to develop a biodegradable polymer DES ahead of the market will make it a technology leader in this field. It is getting crowded. The last count of the competitive space of DES came up to 33 entities. Although some of these have been acquired (e.g. Conor), we still consider them competitors in this space as their R&D teams and operations are likely to continue to function as usual prior to acquisition. Putting aside the 4 main players, BIG currently remains the only entity with a proprietary system complete with Delivery System, Stent and Drug. Once granted the CE mark, BIG would also be the only entity worldwide that would be selling a biodegradable polymer DES after Conor?s sudden withdrawal from the market. Watching for good things. We believe that the yearly pilgrimage by companies and cardiovascular doctors to the Transcatheter Cardiovascular Therapeutics conference will see more positive news for DES. We are expecting BIG to present follow-up studies of its BEACON (12 month) and STEALTH (36 months) trials and anticipate positive results. * I would like to add that CE delay has been around one year and 6 months longer than Conor at this moment and not the 6 months as reported above. BIG submitted CE application only 2 months after Conor and Conor had their CE long long time ago (I think in Q1 of 2006). Conor as we know is a farce from beginning to the end and CE approved them long time ago and the best DES Biomatrix is still stuck at approval. Confirm got kelong at CE! Also, out of the 33 DES players, 4 other entities namely JWMS, Terumo, Devax and Xtent are same gang members under BIG. Also, expect Terumo to present NOBORI (BIOMATRIX) 9 months in detail at TCT2007. Biosensors will most likely present the first 1,000 of of 1,700 patient s that has completed 6 months LEADERS trial by TCT2007 conference. I think BIG will receive much more global recognition after TCT2007.
Useful To Me  Not Useful To Me
bengster68 Master	13-Sep-2007 14:24        bengster68 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Endeavor's in segment late-loss is so huge that they missed their primary end-point against Cypher stents. Arteries renarrowing and reclogging due to poor healing and bad scarring. However, their late-thrombosis problem is most impressive at the present moment (4 years still no thrombosis problems). However, BMS has no thrombosis problems and high late-loss like Endeavor so very little performance difference between high grade BMS and Endeavor. Medtronic also likes to change goal posts of end-point measurements in their trials to cover-up Endeavor's weakness. Endeavor is definitely no suitable for smaller arteries due to very high late-loss. They may get their FDA, but it is a second rated DES. But even second rated DES can also make tons of mooney once approval is obtained. Imagine what will happen if the best DES (Biomatrix) is approved???
Useful To Me  Not Useful To Me
novena_33 Veteran	13-Sep-2007 09:30        novena_33 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hey Mr JackJames.... fyi http://uk.biz.yahoo.com/12092007/323/medtronic-fda-review-endeavor-stent.html Mr Bengster mentioned below....Medtronic's DES Endeavor results are weak in my opinion, performance comparable to Biosensor's S-stent BMS
Useful To Me  Not Useful To Me
abc2xyz Senior	13-Sep-2007 09:27        abc2xyz About Contact  Quote this Post! Style: Flexible   Mood: Yells: "A stock sucker always enriches the market makers"
x 0   x 0  Alert Admin	Good luck and huat huat huat Bengster and all loyalists and faithfuls of Biosensors. Today, I see Biosensors cheong.  A good showing.  Though I have left the battle, I still congratulate all of you and feel that as long as you did you calculations, you will reap what you harvest, and hopefully a plentiful one. I'll reenter once it shows a breakout.  80c if it takes a bit longer and 85c if soon. Happy for all of you.
Useful To Me  Not Useful To Me
novena_33 Veteran	13-Sep-2007 09:17        novena_33 About Contact  Quote this Post!
x 0   x 0  Alert Admin
Useful To Me  Not Useful To Me
bengster68 Master	11-Sep-2007 11:18        bengster68 About Contact  Quote this Post!
x 0   x 0  Alert Admin	To abc2xyz: I respect your decision and wish you all the best. Hope you Huat everywhere you go. However, I believe NOBORI results will announce very soon and will set the share price on uptrend again. The expected news in Sep is NOBORI. Expected news for Oct is TCT2007 partial 6 months LEADERS trial results against JNJ's Cypher and CE approval. When CE comes out, Biosensors will prepare for US listing. I think the final issue price will be finalised after EuroPCR in May 2008 where full 9 months LEADERS trial results will be announced so Biosensors can have a high valuation after sucessful LEADERS trial results. I think by then FDA's IDE should be in the pocket already. June 2008 will be the last chance for any takeover to happen cost effectively for the buyer because it will be even more costly to takeover Biosensors after US listing. Biosensors are fighting against giant MNCs that are at least 100 times bigger and we need to raise money to be bigger and fight with them in global arena. Alternatively if a really good offer to buy us up comes along, I think the key shareholders will consider it. Basically I think $3 offer by end of this year would be a good price for them. By June 2008 they will be looking at $3.50 per share. The buyer has to pay a premium for certainty of LEADERS trial performance. I think our China's JW planning for listing in US in 2008 also to fight against China's Mircoport in 3rd world markets. Biosensors have plan to bring up the valuation of this company. They know their stent technology is the best globally and they are very confident they can win all the trials against any other DES rivals but obtaining regulatory approvals on time is beyond Biosensor's control. I have full confidence Biomatrix's results will shine for all rivals only to envy us. When it comes to approvals, expect the unexpected delays because of business rivals lobbying for delay at the approval process. NOBORI 1 phase 2 (BIOMATRIX) will win again by wide margins in all primary and secondary end-point measurements. In fact, JNJ's $1.70 offer came in somewhere end Oct 2006 shortly after release of NOBORI 1 phase 1 results but this offer was rejected by key controlling shareholders/close associates. JNJ was very impressed with NOBORI's trial performance last year. Biomatrix results are even better than Xience V results. Xience V as we know are developed with Biosensor's help back in 2003 via Guidant partnership. Medtronic's DES Endeavor results are weak in my opinion, performance comparable to Biosensor's S-stent BMS. Thats how good Biosensor's stent technology is. Biosensor's drug and stent technology is way above the performance of all other DES.
Useful To Me  Not Useful To Me
singaporegal Supreme	10-Sep-2007 21:10        singaporegal About Contact  Quote this Post! Style: Technical   Mood: Yells: "Female TA nut"
x 0   x 0  Alert Admin	TA charts still look bearish to me.
Useful To Me  Not Useful To Me

                                                         First   < Newer   10421-10440 of 10899   Older>   Last